RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Embolotherapy of pulmonary arteriovenous malformations: efficacy of platinum versus stainless steel coils.

PURPOSE: To compare the results of embolotherapy of pulmonary arteriovenous malformations (PAVMs) with use of platinum versus stainless-steel coils.

MATERIALS AND METHODS: From a database of 78 consecutive patients with PAVMs treated by embolotherapy between May 1992 and September 2001, 54 patients with 306 PAVMs were selected for retrospective evaluation. Exclusion criteria were PAVMs with less than 12 months of follow-up computed tomography (CT) of the thorax (n = 15), embolotherapy with a mixture of embolic materials (n = 8), and repeat embolotherapy for previous treatment failures (n = 1). Successful treatment was defined as complete resolution of the aneurysm sac and draining vein on follow-up CT (all patients) and/or absence of contrast material flow through the PAVM on pulmonary angiography (n = 27).

RESULTS: Of 267 PAVMs embolized with stainless-steel coils, 249 (93.3%) were successfully occluded (mean follow-up, 3.1 years). Of 39 PAVMs embolized with platinum coils, 35 (89.7%) were successfully occluded (mean follow-up, 2.1 years). There was no significant difference in success between the two groups (P =.5). The mean feeding artery size was significantly larger (P <.0001) in the platinum group (4.3 mm) than in the stainless-steel group (3.5 mm). Potentially serious complications included coil reflux (n = 3), PAVM perforation (n = 2), self-limited neurologic deficit (n = 2), and systemic embolization of a coil (n = 1) in the stainless-steel group, and PAVM perforation (n = 2) in the platinum group. There were no long-term sequelae.

CONCLUSIONS: Coil embolotherapy is highly efficacious, with no statistically significant difference between platinum and stainless-steel coils. The slightly higher proportion of sustained occlusion with stainless-steel coils may be partly explained by the larger mean feeding artery size in the platinum group. The study is limited by the small sample size of the platinum group.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app